Af­ter #ASH22: Post-mortem analy­sis on biggest Twit­ter buzz around drugs, stud­ies and bio­phar­mas

The Amer­i­can So­ci­ety of Hema­tol­ogy (ASH) con­fer­ence end­ed Tues­day and is the “most com­pre­hen­sive hema­tol­ogy event of the year,” so it’s no sur­prise that Twit­ter was abuzz with the hema­tol­ogy and blood can­cer re­search and drug news this week. But what got the biggest buzz? Glob­al­Da­ta’s post-mortem analy­sis broke out the lead­ing top­ics, themes and in­flu­encers from ASH on Twit­ter.

Among the top bio­phar­ma com­pa­nies trend­ing were blue­bird bio, Adap­tive Biotech, As­traZeneca and Ar­cel­lx. The cor­po­rate Twit­ter posts pro­mot­ed hema­tol­ogy and blood can­cer sci­ence com­mit­ments, and pre­sent­ed re­search or in­vit­ed at­ten­dees to stop by com­pa­ny booths for a vis­it.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER